

**B7-H3/CD276**  
**Catalog # PVGS1761****Specification**

---

**B7-H3/CD276 - Product Information**

Primary Accession [Q5ZPR3-2](#)  
**Species**  
Human

**Sequence**  
Leu29-Pro245

**Purity**  
> 95% as determined by Bis-Tris PAGE  
> 95% as determined by HPLC

**Endotoxin Level**  
Less than 1EU per µg by the LAL method.

**Biological Activity**  
Immobilized B7-H3/CD276 hFc Chimera, Human (Cat.No.: Z03881) at 2 µg/ml (100 µl/Well) on the plate can bind Biotinylated Anti-B7-H3 Antibody, hFc Tag.

**Expression System**  
HEK293

**Theoretical Molecular Weight**  
50.1 kDa

Formulation **Lyophilized from a 0.22 µm filtered solution in PBS, pH 7.4.**

**Reconstitution**  
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH<sub>2</sub>O more than 100 µg/ml.

**Storage & Stability**  
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

**B7-H3/CD276 - Additional Information**

**Target Background**  
B7-H3, a member of the B7 family of immunomodulatory molecules, is overexpressed in a wide range of solid cancers. B7-H3 binds to activated T cells via an as yet unidentified receptor. In assays using sub-optimal amount so anti-CD3 stimulation, 2Ig-B7-H3 enhances T cell proliferation, T cell interferon-gamma (IFN-gamma) production, and cytotoxic T cells induction.

**B7-H3/CD276 - Protein Information**

**B7-H3/CD276 - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

**B7-H3/CD276 - Images**